FAKTOR OPTIONSSCHEIN - IDORSIA | Delayed Deutsche Boerse AG 13:21:30 17/05/2024 BST | ||
| 0.3 EUR | +11.11% |
|
| Current month | -46.00% | ||
| 1 month | -37.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.3 | +11.11% |
| 16/05/24 | 0.27 | -3.57% |
| 15/05/24 | 0.28 | -6.67% |
| 14/05/24 | 0.3 | +7.14% |
| 13/05/24 | 0.28 | -17.65% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 01:21 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | 
BNP Paribas
|
| WKN | PD2P1D |
| ISIN | DE000PD2P1D9 |
| Date issued | 10/12/2021 |
| Strike | 2.352 CHF |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 200 € |
|---|---|
| Lowest since issue | 0.27 € |
| Spread | -0.02 € |
| Spread % | 7.14% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.352
CHF
Average target price
1.724
CHF
Spread / Average Target
-26.71%
- Stock Market
- Certificates
- Certificat
